The First Experience of Pulmonary Veno-occlusive Disease Treatment With Macitentan and Sildenafil

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Experiencia única con macitentán y sildenafilo en el tratamiento de la enfermedad venooclusiva pulmonar To the Editor, Pulmonary veno-occlusive disease (PVOD) is a rare cause of pulmonary arterial hypertension. PVOD shares many character-istics with idiopathic pulmonary arterial hypertension, making it very difficult to distinguish between these conditions. Accurate diagnosis is essential because PVOD has a worse prognosis, and treatment with specific vasodilators can trigger acute pulmonary edema. Currently, the only effective treatment is lung transplan-tation. 1 We present the case of a 74-year-old woman who was initially diagnosed with pulmonary arterial hypertension and was treated with macitentan and sildenafil. The patient showed significant improvement with this treatment, even though subsequent diagnosis revealed that she very likely had PVOD. The patient's medical history included Sjö gren syndrome, diagnosed several years previously based on presentation with dry eyes and a positive antinuclear antibody test. The patient was first admitted in January 2015 with a diagnosis of severe congestive heart and respiratory failure secondary to atrial flutter with a rapid ventricular response. On admission, echocardi-ography revealed evidence of severe pulmonary hypertension and right ventricular dysfunction, whereas left cavity dimensions and function were normal (left atrium anteroposterior diameter, 33 mm). Symptoms improved substantially with diuretic therapy and reversion to sinus rhythm, and the patient was discharged. She was readmitted 1 month later with similar symptoms, but this time in sinus rhythm. The decision was taken to conduct the battery of diagnostic tests recommended for the study of pulmonary hypertension: abdominal ultrasound, serology for hepatotrophic and human immunodeficiency viruses, respiratory function tests, lung computed tomography with contrast, and ventilation-perfu-sion scintigraphy. 2,3 These tests revealed no major involvement. The study was completed with a right-side catheterization that revealed severe pulmonary arterial hypertension (pulmonary artery occlusion pressure, 7 mmHg), with highly elevated pulmo-nary arterial resistance and severely impaired cardiac output (Table). A nitric oxide vasodilation test conducted during the same catheterization was positive according to current guidelines, 2,3 and treatment was therefore commenced with calcium antagonists. The patient showed a good initial response to increasing doses of amlodipine; however, at the end of May she was readmitted with congestive heart failure. A diagnostic review revealed that the patient had limited systemic sclerosis (calcinosis, telangiectasias, microstomia, Ray-naud phenomenon, and positive tests for anti-centromere, anti-sp100, and anti-pM-scl antibodies). The worsening condition was attributed to the nonresponsiveness of patients in this subgroup, and the decision was taken to start treatment with macitentan at 10 mg/d. The response over the following months was clearly satisfactory, albeit insufficient. In September 2015 sildenafil was added at a dose of 20 mg/8 h, and a few weeks later the patient was once again admitted with worsening breathlessness and congestive heart failure. A cardiac nuclear magnetic resonance examination showed no signs of left heart disease and indicated acceptable right ventricle function. Repeat right heart catheterization confirmed clear improvement in cardiac output and pulmonary artery resistance (Table). Even after administration of 500 mL physiological saline solution, the pulmonary artery occlusion pressure remained below 17 mmHg at all times, definitively excluding a combination of heart failure with preserved ejection fraction. A high-resolution lung computed tomography scan was requested and demonstrated a centrilobular distribution of nodular ground-glass opacities, mediastinal lymphadenopathies of up to 3.8 cm diameter, and septal thickening (Figure). In repeat tests, all respiratory functions were normal except for extremely low lung carbon monoxide diffusion capacity (DLCO) after adjustment for alveolar volume (DLCO/AV 44%) and severe chronic hypoxemia. Together, these findings very strongly suggested that the patient had PVOD associated with systemic sclerosis. Today, more than 1 year after symptom onset, the patient is in dyspnea functional class II/IV. Her condition shows no sign of deterioration, her brain natriuretic peptide concentration is normal, her 6-minute walk distance is about 325 m, and her echocardiography-measured right-ventricular function parame-ters and cavity size are also within the normal range. Her situation is thus stable and satisfactory (Table) and given the risk of complications we have no plans to intensify treatment. Diagnostic confirmation of PVOD requires histological analysis; however, lung biopsy is contraindicated in most patients. Lung computed tomography is currently considered a major diagnostic tool, and the 3 radiological signs found in our patient together give

Cite

CITATION STYLE

APA

Chamorro Fernández, C. I., Garcés Cabello, P., Pérez Mateos, R., Sánchez Soriano, R. M., Ferrando Siscar, C., & Quezada Loaiza, C. A. (2017). The First Experience of Pulmonary Veno-occlusive Disease Treatment With Macitentan and Sildenafil. Revista Espanola de Cardiologia, 70(5), 396–397. https://doi.org/10.1016/j.recesp.2016.07.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free